Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.

Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid.

Viking should have plenty of news to share with investors this year.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.

/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual

Viking Therapeutics is still kept as a speculative buy, with selling pressure subsiding and constructive consolidation signaling renewed investor interest. VKTX's dual-track pipeline and manufacturing agreements position it to rapidly scale commercialization upon regulatory approval, despite a volatile and competitive GLP-1 market. Management's flexible go-to-market strategy and recent commercial leadership appointment highlight readiness to compete independently or via partnership.

Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.